clinical trial · NCT07290036
A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
UCB Biopharma SRL·phase1·recruiting·n = 392
Psoriatic ArthritisAxial SpondyloarthritisBimekizumab regimen 1 ivBimekizumab regimen 2 ivBimekizumab regimen 3 sc
brief summary
To demonstrate that bimekizumab administered intravenously is noninferior to subcutaneous administration.
started
Dec 10, 2025
primary completion
May 18, 2028
completion
Sep 14, 2028
last updated
Apr 24, 2026
official title
An Open-label, Randomized, Parallel-group, Noninferiority Study to Evaluate the Pharmacokinetics of Bimekizumab Administered Intravenously or as a Subcutaneous Injection in Participants With Active Psoriatic Arthritis and/or Active Axial Spondyloarthritis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol